Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy



Survival: 13.1 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
   
Drugs:
Country: Italy
   
City/State/Province: Napoli
   
Hospital: Istituto Nazionale Tumori Fondazione Pascale
   
Journal: Link
   
Date: 9/2013

Description:
Patients:
This phase 2 study involved metastatic melanoma patients who were divided into separate groups based on the specific genetic mutation of their cancer. Group A consisted of 76 patients with the BRAF V600E mutation. Group B consisted of 16 patients with the BRAF V600K mutation. The median patient age for the total group of patients was 55.5 years and 53% of all patients were male.

Treatment:
Patients in both groups received biologic therapy with dabrafenib, which is a BRAF kinase inhibitor that interferes with cancer cell growth.

Toxicities:
The most severe toxicities in the total group of patients were of grade 4, but were not specified. Grade 3 arthralgia (joint pain), headache, anemia, and cutaneous squamous cell carcinoma were reported.

Results:
The median overall survival rates for groups A and B were 13.1 and 12.9 months, respectively.

Support:
This study was supported by GlaxoSmithKline.

Correspondence: Dr. Paolo A. Ascierto; email: paolo.ascierto@gmail.com

E-mail to a Friend Email Physician More Information